Ferring Firmagon’s “Positive” NICE Recommendation Still Not That Good
This article was originally published in The Pink Sheet Daily
Executive Summary
Severely restricted indication will see the prostate cancer drug’s revenues effectively dry up in the U.K.
You may also be interested in...
Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals
Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.